Vaccinations against the SARS-CoV-2 KP.2 variant were introduced for the 2024-25 season in the United States. Here, the authors investigate the effectiveness of these vaccines up to April 2025 through a target trial emulation study using electronic health record data.
- George N. Ioannou
- Kristin Berry
- Kristina L. Bajema
